Prothena（PRTA）株式概要
後期臨床バイオテクノロジー企業であるProthena Corporation plcは、タンパク質の調節異常によって引き起こされる疾患を治療するための新規治療法の発見と開発に注力している。 詳細
PRTA Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Prothena Corporation plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$9.69 |
| 52週高値 | US$11.80 |
| 52週安値 | US$6.16 |
| ベータ | -0.32 |
| 1ヶ月の変化 | 5.44% |
| 3ヶ月変化 | -1.72% |
| 1年変化 | 50.58% |
| 3年間の変化 | -85.54% |
| 5年間の変化 | -82.45% |
| IPOからの変化 | 34.58% |
最新ニュース
ナラティブの更新 • Jun 25
PRTA: Fast Track ATTR Cardio Program And Tau Data Will Support Upside
Analysts kept their fair value estimate for Prothena steady at $21.40 while making only minimal model tweaks, citing broader enthusiasm around tau-targeting Alzheimer's therapies following the CELIA Phase 2 data as a key support for the updated price target framework. What’s in the News for Prothena U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for treating ATTR cardiomyopathy (ATTR-CM), according to Prothena’s update on the Novo Nordisk partnered program.ナラティブの更新 • Jun 04
PRTA: Fast Track ATTR Program And Tau Readthroughs Will Support Future Upside
Analysts have nudged their fair value estimate for Prothena stock from $21.00 to $21.40, citing updated assumptions on long term revenue growth, profit margins, and future P/E multiples following fresh readthroughs from recent Alzheimer's tau data. What's in the News The U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).Recent updates
ナラティブの更新 • Jun 25
PRTA: Fast Track ATTR Cardio Program And Tau Data Will Support Upside
Analysts kept their fair value estimate for Prothena steady at $21.40 while making only minimal model tweaks, citing broader enthusiasm around tau-targeting Alzheimer's therapies following the CELIA Phase 2 data as a key support for the updated price target framework. What’s in the News for Prothena U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for treating ATTR cardiomyopathy (ATTR-CM), according to Prothena’s update on the Novo Nordisk partnered program.ナラティブの更新 • Jun 04
PRTA: Fast Track ATTR Program And Tau Readthroughs Will Support Future Upside
Analysts have nudged their fair value estimate for Prothena stock from $21.00 to $21.40, citing updated assumptions on long term revenue growth, profit margins, and future P/E multiples following fresh readthroughs from recent Alzheimer's tau data. What's in the News The U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).ナラティブの更新 • May 09
PRTA: Fast Track ATTR Program And Buybacks Will Support Future Upside
Analysts kept Prothena's fair value estimate steady at $21.00 with only small tweaks to the discount rate and long term assumptions, suggesting their price target is broadly unchanged while refining the supporting model inputs. What's in the News The U.S. FDA granted Fast Track Designation to coramitug, an amyloid depleter antibody in Phase 3 development for transthyretin amyloidosis with cardiomyopathy.ナラティブの更新 • Apr 22
PRTA: ATTR Milestones And Share Repurchase Plan Will Support Future Upside
Analysts maintained Prothena's fair value estimate at $21.00, citing largely unchanged assumptions regarding revenue growth, profit margin, discount rate, and a very large future P/E multiple. What's in the News Prothena has earned $150 million to date out of up to $1.2 billion in eligible milestone payments from Novo Nordisk under their ATTR amyloidosis agreement.ナラティブの更新 • Apr 02
PRTA: ATTR Milestones And Share Repurchase Will Drive Future Upside
Analysts have kept their price target for Prothena broadly unchanged at $21.00, with only slight adjustments to underlying assumptions on discount rate, revenue growth, profit margin and future P/E, in order to better reflect their current view of the stock's risk and earnings profile. What's in the News Prothena has earned $150 million to date of the total eligible milestone payments of up to $1.2 billion from Novo Nordisk under their ATTR amyloidosis agreement, including a recent $50 million milestone tied to a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA trial of coramitug for ATTR-CM (Key Developments).ナラティブの更新 • Mar 19
PRTA: Share Buyback And ATTR Milestones Will Support Future Upside
Analysts have nudged their price target on Prothena to $21.00 from $20.50, reflecting updated assumptions on growth, margins, and a very large prospective future P/E multiple. What's in the News Prothena has earned a total of $150 million to date from potential milestone payments of up to $1.2 billion under its ATTR amyloidosis agreement with Novo Nordisk, tied to clinical development and sales milestones (Key Developments).ナラティブの更新 • Mar 04
PRTA: Share Buyback And Index Inclusion Will Support Future Upside
Analysts now set their Prothena price target at about $20.50, compared with roughly $20.33 previously. This reflects updated assumptions around revenue growth, profit margins and future P/E levels.
新しいナラティブ • Feb 23
Bullish View Expects Partnered Neurology Pipeline And CYTOPE Platform To Reshape Long-Term Prospects
Catalysts About Prothena Prothena is a late stage biotech company focused on protein misfolding and neurodegenerative diseases through partnered and wholly owned antibody and CYTOPE programs. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 18
PRTA: Index Inclusion And ALS Platform Milestones Will Drive Future Upside
Analysts maintained their Prothena fair value estimate at $20.33 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this unchanged price target. What's in the News Prothena Corporation plc was added to the S&P Biotechnology Select Industry Index, which can increase visibility for the stock among index-tracking funds and sector-focused investors (Key Developments).ナラティブの更新 • Feb 03
PRTA: Future Milestones From ALS Platform And ATTR Program Will Drive Upside
Analysts have trimmed their price target for Prothena to about US$20.33 per share, reflecting slightly adjusted assumptions around discount rate, profit margin, and future P/E that fine tune rather than overhaul their prior view. What's in the News Prothena was added to the S&P Biotechnology Select Industry Index, putting the stock into a tracked industry benchmark that some index funds and ETFs follow (Index Constituent Adds).ナラティブの更新 • Jan 20
PRTA: Partnered Royalties And Milestones Will Drive Upside Over Next 12 Months
Narrative update Analysts have lifted their price target on Prothena to US$36 from US$15, highlighting the value they see in the partnered pipeline and its potential for net sales royalties and milestone payments over the catalyst-heavy year ahead. Analyst Commentary Bullish analysts are pointing to the recent price target revision to US$36 as a signal that the market may be underappreciating the potential value of Prothena's partnered programs, especially the royalty and milestone streams that could build over time.ナラティブの更新 • Jan 05
PRTA: Partnered Royalties And Milestones Will Drive Upside Over Catalyst-Rich Year
Narrative Update Analysts have raised their price target on Prothena to US$36 from US$15, citing what they describe as strong potential in the company's partnered pipeline, including expected net sales royalties and milestone payments over the coming year and in subsequent periods. Analyst Commentary Recent commentary from bullish analysts centers on the uplift in the price target to US$36, tied directly to how they see Prothena executing on its partnered programs and the potential cash flows that could come from those collaborations.ナラティブの更新 • Dec 18
PRTA: Partnered Pipeline Milestones Will Drive Upside Over Catalyst-Rich Year Ahead
Analysts have significantly raised their price target on Prothena to $36 from $15, reflecting increased confidence in the lucrative potential of its partnered pipeline, including expected net sales royalties, milestone payments, and a catalyst-rich outlook over the next year. Analyst Commentary Bullish analysts highlight that the substantial price target increase is grounded in greater conviction around Prothena's partnered pipeline, which they see as a key driver of long term value creation and multiple expansion.分析記事 • Dec 11
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...ナラティブの更新 • Dec 04
PRTA: Partnered Pipeline Milestones Will Drive Upside Over Catalyst-Rich Year Ahead
Analysts have lifted their fair value estimate for Prothena by about $2 per share, citing stronger long term revenue growth expectations from its partnered pipeline, lucrative royalty and milestone economics, and a robust catalyst calendar that they believe offers substantial upside potential. Analyst Commentary Recent adjustments to Prothena's valuation reflect a growing conviction that the company’s partnered programs and associated economics could materially enhance long term growth, though execution and timing risks remain key variables for investors.ナラティブの更新 • Nov 20
PRTA: Upcoming Partnered Pipeline Milestones Will Drive Substantial Upside Over Next Year
Analysts have increased their price target for Prothena, raising it from $16.50 to $18.33. They cite optimism about the company's partnered pipeline and upcoming catalysts as key drivers for this upward revision.ナラティブの更新 • Nov 05
PRTA: Upcoming Pipeline Milestones Will Drive Bullish Momentum Over Next 12 Months
Analysts have increased their price target for Prothena significantly, raising it from $15 to $36. They cite the company's strong partnered pipeline as well as substantial potential from upcoming catalysts and milestone payments.ナラティブの更新 • Oct 22
Analysts Maintain Prothena Price Target as Valuation Adjustments Reflect Recent Clinical Results
Analysts have marginally raised their price target for Prothena from $13.00 to $13.00. They cited slight adjustments in discount rate and profit margin assumptions as drivers for the updated valuation.ナラティブの更新 • Oct 08
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Analysts have raised Prothena's fair value estimate by $1.00 to $13.00, citing improved profit margin forecasts and a slightly lower projected future price-to-earnings ratio. What's in the News Prothena announced results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease.ナラティブの更新 • Sep 13
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Prothena’s consensus price target has been revised down to $12.00, reflecting weaker expectations primarily due to a notable decline in net profit margin and a reduced future P/E multiple. What's in the News Prothena reported Phase 1 ASCENT program results for PRX012 in early symptomatic Alzheimer's, showing stable pharmacokinetics, low immunogenicity, significant amyloid reduction, but higher ARIA-E rates compared to FDA-approved antibodies; company plans to seek partnerships for PRX012 and PRX012-TfR.ナラティブの更新 • Aug 29
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Despite a sharp upward revision in both revenue growth and net profit margin forecasts for Prothena, the consensus analyst price target has significantly decreased from $24.29 to $15.00. What's in the News Phase 1 ASCENT results for PRX012 in early symptomatic Alzheimer's showed promising amyloid plaque reduction and pharmacokinetics, but higher ARIA-E rates than approved therapies; Prothena will seek partnership to advance PRX012 and its preclinical Ab-TfR antibody.分析記事 • May 29
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on Prothena Corporation plc ( NASDAQ:PRTA ) - they aren't optimistic, having...Seeking Alpha • May 27
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place
Summary Prothena Corporation plc's phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis failed, leading to program termination and workforce reduction. Despite Phase 3 AL Amyloidosis trial failure, I maintain a Hold rating due to Prothena's robust pipeline, including Alzheimer's, Parkinson's, and ATTR-CM candidates. Key near-term catalysts include phase 1 PRX012 Alzheimer's data mid-2025 and other releases going forward, plus data updates for candidates prasinezumab and coramitug for PD and ATTR-CM. The Alzheimer's Disease market, in the 8 major markets [8MM] is expected to reach $19.3 billion by 2033; About between 5% to 6% of AD patients are early-symptomatic. Read the full article on Seeking Alpha分析記事 • May 22
Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge
Unfortunately for some shareholders, the Prothena Corporation plc ( NASDAQ:PRTA ) share price has dived 27% in the last...分析記事 • Apr 02
Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
Prothena Corporation plc ( NASDAQ:PRTA ) shares have had a horrible month, losing 26% after a relatively good period...
新しいナラティブ • Mar 26
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.Seeking Alpha • Mar 03
Prothena Corporation: Multiple Failures Make It Risky
Summary Prothena Corporation focuses on neurodegenerative diseases with a diverse pipeline, including Birtamimab for AL amyloidosis, which is in a phase 3 trial. Despite past trial failures, Birtamimab showed a survival benefit in severe AL amyloidosis patients, leading to a new phase 3 study. Financially, Prothena has a market cap of $850mn and a cash runway of 5-10 quarters, but is heavily spending on R&D. I recommend avoiding PRTA due to unpredictable upcoming data and past trial failures, making it risky and potentially un-investible. Read the full article on Seeking Alpha分析記事 • Feb 22
Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think
It's been a good week for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, because the company has just released...分析記事 • Jan 24
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 6.2x Prothena Corporation plc ( NASDAQ:PRTA ) may be sending bullish signals...Seeking Alpha • Dec 22
Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Summary Prothena's stock surged 34% despite Prasinezumab missing its Phase IIb primary endpoint, as Roche continues to invest. Prothena's pipeline includes multiple clinically staged drugs, with partnerships with major pharma companies, offering high-risk/high-reward potential. Investors should be cautious due to Prothena's 61% stock decline in 2024, but meaningful clinical success could create a buying opportunity. Prothena is rated as a HOLD, with upcoming catalysts in Parkinson's and Alzheimer's diseases that could fuel significant price appreciation. Read the full article on Seeking Alpha分析記事 • Nov 06
Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Oct 18
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Summary Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful Phase 1 data for PRX012. PRX012, targeting amyloid beta for Alzheimer's, is Prothena's key value driver but remains in Phase 1, lagging competitors with similar drugs. Birtamimab's Phase 3 data has also faced delays, and while promising, it competes in a crowded market with limited patient populations. Despite a strong cash position, Prothena's pipeline progress and competitive landscape justify a downgrade to “Hold” until more substantial data is available. Read the full article on Seeking Alpha分析記事 • Oct 02
Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Prothena Corporation plc ( NASDAQ:PRTA ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Jul 26
Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
You may think that with a price-to-sales (or "P/S") ratio of 14.9x Prothena Corporation plc ( NASDAQ:PRTA ) is a stock...分析記事 • Jun 19
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Jun 07
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Summary Prothena Corporation is a late-stage biotech which specializes in proteinopathies and neurodegenerative diseases. They have a diverse pipeline. However, their main assets in attention currently are a first-in-class amyloid depleter, Birtamimab (wholly owned), and a Parkinson’s a-synuclein mAb, Prasinezumab (collab with Roche). Their revenue is primarily dependent on key milestone payments from collaborators. The stock has been dropping since its peak about a year ago, and I believe it still has room to drop for the foreseeable future due to the risk of failure of late-stage trials. Read the full article on Seeking Alpha分析記事 • May 14
New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
Prothena Corporation plc ( NASDAQ:PRTA ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Feb 23
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients with Alzheimer's Disease in the ongoing phase 3 ASCENT-2 study. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031. BMS-986446 is being advanced in collaboration with Bristol-Myers Squibb with the big pharma having taken over the program going forward; Prothena received a $55 million milestone payment based off of it. Read the full article on Seeking Alpha株主還元
| PRTA | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 4.5% | 5.4% | 1.4% |
| 1Y | 50.6% | 41.5% | 19.1% |
業界別リターン: PRTA過去 1 年間で41.5 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: PRTA過去 1 年間で19.1 % の収益を上げたUS市場を上回りました。
価格変動
| PRTA volatility | |
|---|---|
| PRTA Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: PRTA 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: PRTAの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2012 | 67 | Gene Kinney | www.prothena.com |
後期臨床バイオテクノロジー企業であるProthena Corporation plcは、タンパク質の調節異常によって引き起こされる疾患を治療するための新規治療法の発見と開発に注力している。同社の製品パイプラインには、パーキンソン病やその他のシヌクレイン異常症の治療薬として第3相臨床試験段階にあるヒト化モノクローナル抗体Prasinezumabがある。また、トランスサイレチンアミロイドーシス治療薬として臨床第3相試験中の治験用抗体Coramitug、アルツハイマー病治療薬として臨床第2相試験中の抗タウ抗体BMS-986446、神経変性疾患治療薬として臨床第1相試験中の治験用抗体PRX019、アルツハイマー病治療薬として前臨床試験中のデュアルAß-タウワクチンPRX123も開発しています。さらに、筋萎縮性側索硬化症の治療薬TDP-43 CYTOPE、アルツハイマー病の治療薬として第1相臨床試験中の次世代抗Aß抗体PRX012、アルツハイマー病の治療薬として前臨床試験中のPRX012-TfRなど、発見段階および後期前臨床段階のプログラムも開発している。また、F.ホフマン・ラ・ロシュ社およびホフマン・ラ・ロシュ社とは、プラシネズマブを含むa-シヌクレインを標的とする抗体の開発・商業化に関するライセンス・開発・商業化契約を、ブリストル・マイヤーズ スクイブ社とは、タウ、TDP-43を標的とする抗体の開発・商業化に関するマスターコラボレーション契約を締結している。Prothena Corporation plcは2012年に設立され、アイルランドのダブリンに本社を置いている。
Prothena Corporation plc 基礎のまとめ
| PRTA 基礎統計学 | |
|---|---|
| 時価総額 | US$501.54m |
| 収益（TTM） | -US$151.18m |
| 売上高(TTM) | US$57.94m |
8.8x
P/Sレシオ-3.4x
PER（株価収益率PRTA は割高か？
公正価値と評価分析を参照収益と収入
| PRTA 損益計算書（TTM） | |
|---|---|
| 収益 | US$57.94m |
| 売上原価 | US$96.67m |
| 売上総利益 | -US$38.73m |
| その他の費用 | US$112.45m |
| 収益 | -US$151.18m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.89 |
| グロス・マージン | -66.84% |
| 純利益率 | -260.92% |
| 有利子負債／自己資本比率 | 0% |
PRTA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/02 07:17 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Prothena Corporation plc 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24
| アナリスト | 機関 |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |